Integrity of p53 in hepatitis B x antigen-positive and -negative hepatocellular carcinomas

Cancer Research

Volumn 57, Issue 3, 1997, Pages 426-432

  Greenblatt, M S ^a   Feitelson, M A ^c   Zhu, M ^d   Bennett, W P ^a   Welsh, J A ^a   Jones, R ^b   Borkowski, A ^b   Harris, C C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIGEN; PROTEIN P53;

ANTIGEN DETECTION; ARTICLE; GENE ACTIVATION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MUTATION RATE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE;

CARCINOMA, HEPATOCELLULAR; HEPATITIS B ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MUTATION; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031043425     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Yarrish, R. L., Werner, B. J., and Blumberg, B. S. Association of hepatitis B virus infection with hepatocellular carcinoma in American patients. Int. J. Cancer, 26: 711-715, 1980.
2. Tabor, E., Gerety, R. J., Voegel, C. L., Bayley, A. L., Anthony, P. P., Chen, C. H., and Barker, L. F. Hepatitis B virus infection and primary hepatocellular carcinoma. J. Natl. Cancer Inst., 58: 1197-1200, 1977.
3. Beasley, R. P. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer (Phila.), 61: 1942-1956, 1988.
4. Qian, G. S., Ross, R. K., Tu, M. C., Yuan, J. M., Gao, Y. T., Henderson, B. E., Wogan, G. N., and Groopman, J. D. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol., Biomarkers & Prev., 3: 3-10, 1994.
5. 1. Proc. Natl. Acad. Sci. USA, 92: 2384-2387, 1995.
6. Feitelson, M. A. Biology of disease. Biology of hepatitis B virus variants, Lab. Invest., 71: 324-349, 1994.
7. Robinson, W. S., Klote, L., and Aoki, N. Hepadnaviruses in cirrhotic liver and hepatocellular carcinoma. J. Med. Virol., 31: 18-32, 1990.
8. Okuda, K. Hepatocellular carcinoma: recent progress. Hepatology, 15: 948-963, 1992.
9. Feitelson, M. A. Hepatitis B virus infection and primary hepatocellular carcinoma. Clin. Microbiol. Rev., 5: 275-301, 1992.
10. Graef, E., Caselmann, W. H., Wells, J., and Koshy, R. Insertional activation of mevalonate kinase by hepatitis B virus DNA in a human hepatoma cell line. Oncogene, 9: 81-87, 1994.
11. Hatada, I., Tokino, T., Ochiya, T., and Matsubara, K. Co-amplification of integrated hepatitis B virus DNA and transforming gene hsl-1 in a hepatocellular carcinoma. Oncogene, 3: 537-540, 1988.
12. Cariani, E., Lasserre, C., Kemeny, F., Franco, D., and Brechot, C. Expression of insulin-like growth factor II, α-fetoprotein, and hepatitis B virus transcripts in human primary liver cancer. Hepatology, 13: 644-649, 1991.
13. Richards, C. A., Short, S. A., Thorgeirsson, S. S., and Huber, B. E. Characterization of a transforming N-ras gene in the human hepatoma cell line Hep G2: additional evidence for the importance of c-myc and ras cooperation in hepatocarcinogenesis. Cancer Res., 50: 1521-1527, 1990.
14. Dejean, A., Bougueleret, L., Grzeschik, K. H., and Tiollais, P. Hepatitis B virus DNA integration in a sequence homologous to v-erb-A and steroid receptor genes in a hepatocellular carcinoma. Nature (Lond.), 322: 70-72, 1986.
15. Wang, J., Zindy, F., Chenivesse, X., Lamas, E., Henglein, B., and Brechot, C. Modification of cyclin A expression by hepatitis B virus DNA integration in a hepatocellular carcinoma. Oncogene, 7: 1653-1656, 1992.
16. Zahm, P., Hofschneider, P. H., and Koshy, R. The HBV X-ORF encodes a transactivator: a potential factor in viral hepatocarcinogenesis. Oncogene, 3: 169-177, 1988.
17. Cross, J. C., Wen, P., and Rutter, W. J. Transactivation by hepatitis B virus X protein is promiscuous and dependent on mitogen-activated cellular serine/threonine kinases. Proc. Natl. Acad. Sci. USA, 90: 8078-8082, 1993.
18. Kekule, A. S., Lauer, U., Weiss, L., Luber, B., and Hofschneider, P. H. Hepatitis B virus transac tivator HBx uses a tumor promoter signaling pathway. Nature (Lond.), 361: 742-745, 1993.
19. Benn, J., and Schneider, R. J. Hepatitis B virus HBx protein activates ras-GTP complex formation and establishes a ras, raf, MAP kinase signaling cascade. Proc. Natl. Acad. Sci. USA, 91: 10350-10354, 1994.
20. Natoli, G., Avantaggiati, M. L., Chirillo, P., Puri, P. L., Ianni, A., Balsano, C., and Levrero, M. Ras- and raf-dependent activation of c-Jun transe optional activity by the hepatitis B virus transactivator pX. Oncogene, 9: 2837-2843, 1994.
21. Benn, J., and Schneider, R. J. Hepatitis B virus HBx protein deregulates cell cycle checkpoint controls. Proc. Natl. Acad. Sci. USA, 92: 11215-11219, 1995.
22. Koike, K., Moriya, K., Yotsuyanagi, H., Iino, S., and Kurokawa, K. Induction of cell cycle progression by hepatitis B virus HBx gene expression in quiescent mouse fibroblasts. J. Clin. Invest., 94: 44-49, 1994.
23. Hohne, M., Schaefer, S., Seifer, M., Feitelson, M. A., Paul, D., and Gerlich, W. H. Malignant transformation of immortalized transgenic hepatocytes after transfection with hepatitis B virus DNA. EMBO J., 9: 1137-1145, 1990.
24. Kim, C. M., Koike, K., Saito, I., Miyamura, T., and Jay, G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature (Lond.), 351: 317-320, 1991.
25. Koike, K., Moriya, K., Iino, S., Yotsuyanagi, H., Endo, Y., Miyamura, T., and Kurokawa, K. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology, 19: 810-819, 1994.
26. Maguire, H. F., Hoeffler, J. P., and Siddiqui, A. HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions. Science (Washington DC), 252: 842-844, 1991.
27. Qadri, I., Maguire, H. F., and Siddiqui, A. Hepatitis B virus transactivator protein X interacts with the TATA-binding protein. Proc. Natl. Acad. Sci. USA, 92: 1003-1007, 1995.
28. Cheong, J. H., Yi, M. K., Lin, Y., and Murakami, S. Human RPB5, a subunit shared by eukaryotic nuclear RNA polymerases, binds human hepatitis B virus X protein and may play a role in X transactivation. EMBO J., 14: 143-150, 1995.
29. Lee, T. H., Elledge, S. J., and Butel, J. S. Hepatitis B virus X protein interacts with a probable cellular DNA repair protein. J. Virol., 69: 1107-1114, 1995.
30. Feitelson, M. A., Zhu, M., Duan, L. X., and London, W. T., Hepatitis B x antigen and p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene, 8: 1109-1117, 1993.
31. Wang, X. W., Forrester, K., Yeh, H., Feitelson, M. A., Gu, J. R., and Harris, C. C. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc. Natl. Acad. Sci. USA, 91: 2230-2234, 1994.
32. Ueda, H., Ullrich, S. J., Gangemi, J. D., Kappel, C. A., Ngo, L., Feitelson, M. A., and Jay, G. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat. Genet., 9: 41-47, 1995.
33. Wang, X. W., Gibson, M. K., Vermeulen, W., Yeh, H., Forrester, K., Sturzbecher, H-W., Hoeijmakers, J. H. J., and Harris, C. C. Abrogation of p53-induced apoptosis by the hepatitis B virus X gene. Cancer Res., 55: 6012-6016, 1995.
34. Ding, S. F., and Habib, N. A. Loss of heterozygosity in liver tumors. J. Hepatol., 22: 230-238, 1995.
35. Hsu, H. C., Peng, S. Y., Lai, P. L., Sheu, J. C., Chen, D. S., Lin, L. L., Slagle, B. L., and Butel, J. S. Allelotype and loss of heterozygosity of p53 in primary and recurrent hepatocellular carcinomas. Cancer (Phila.), 73: 42-47, 1994.
36. Zhou, Y. Z., Slagle, B. L., Donehower, L. A., van Tuinen, P., Ledbetter, D. H., and Butel, J. S. Structural analysis of a hepatitis B virus genome integrated into chromosome 17p of a human hepatocellular carcinoma. J. Virol., 62: 4224-4231, 1988.
37. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 55: 4855-4878, 1994.
38. Harris, C. C. Solving the viral-chemical puzzle of human liver carcinogenesis. Cancer Epidemiol., Biomarkers & Prev., 3: 1-2, 1994.
39. Hsu, H. C., Peng, S. Y., Lai, P. L., Chu, J. S., and Lee, P. H. Mutations of p53 gene in hepatocellular carcinoma (HCC) correlate with tumor progression and patient prognosis: a study of 138 patients with unifocal HCC. Int. J. Oncol., 4: 1341-1347, 1994.
40. 1 induces the transversion of G:T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc. Natl. Acad. Sci. USA, 90: 8586-8590, 1993.
41. Aguilar, F., Harris, C. C., Sun, T., Hollstein, M., and Cerutti, P. Geographic variation of p53 mutational profile in nonmalignam human liver. Science (Washington DC), 264: 1317-1319, 1994.
42. Hsu, I. C., Tokiwa, T., Bennett, W., Metcalf, R. A., Welsh, J. A., Sun, T., and Harris, C. C. p53 mutations and integrated hepatitis B viral DNA sequences in human liver cancer cell lines. Carcinogenesis (Lond.), 14: 987-992, 1993.
43. Puisieux, A., Ponchel, F., and Ozturk, M. p53 as a growth suppressor gene in HBV-related hepatocellular carcinoma cells. Oncogene, 8: 487-490, 1993.
44. Bennett, W. P., Hollstein, M. C., He, A., Zhu, S. M., Resau, J., Trump, B. F., Metcalf, R. A., Welsh, J. A., Gannon, J. V., Lane, D. P., and Harris, C. C. Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. Oncogene, 6: 1779-1784, 1991.
45. Wang, W., London, W. T., Lega, L., and Feitelson, M. A. Hepatitis B x antigen in liver from carrier patients with chronic hepatitis and cirrhosis. Hepatology, 14: 29-37, 1991.
46. Midgley, C. A., Fisher, C. J., Bartek, J., Vojtesek, B., Lane, D. P., and Barnes, D. M. Expression of human p53 in bacteria: application to the analysis of p53 expression in human tumours. J. Cell Sci., 101: 183-189, 1992.
47. Sanger, F., Nicklen, S., and Coulson, A. R. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA, 74: 5463-5467, 1977.
48. Brechot, C., Degos, F., Lugassy, C., Thiers, V., Zafrani, S., Franco, D., Bismuth, H., Trepo, C., Benhamou, J. P., Wands, J., Isselbacher, K., Tiollais, P., and Berthelot, P. Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen. N. Engl. J. M ed., 312: 270-276, 1985.
49. Liang, T. J., Baruch, Y., Ben-Porath, E., Enat, R., Bassan, L., Brown, N. V., Rimon, N., Blum, H. E., and Wands, J. R. Hepatitis B virus infection in patients with idiopathic liver disease. Hepatology, 13: 1044-1051, 1991.
50. Zhu, M., London, W. T., Duan, L-X., and Feitelson, M. A. The value of hepatitis B x antigen as a prognostic marker in the development of hepatocellular carcinoma. Int. J. Cancer, 55: 571-576, 1993.
51. Bourdon, J. C., D'Errico, A., Paterlini, P., Grigioni, W., May, E., and Debuire, B. p53 protein accumulation in European hepatocellular carcinoma is not always dependent on p53 gene mutation. Gastroenterology, 108: 1176-1182, 1995.
52. Di Bisceglie, A. M. Hepatitis C and hepatocellular carcinoma. Semin. Liver Dis., 15: 64-69, 1995.
53. Simonetti, R. G., Camma, C., Fiorella, F., Cottone, M., Rapicetta, M., Marino, L., Florentine, G., Craxi, A., Ciccaglione, A., Giuseppetti, R., Stroffolini, T., and Pagiaro, L. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis: a case control study. Ann. Intern. Med., 116: 97-102, 1992.
54. Feitelson, M. A., Lega, L., Guo, J., Resti, M., Rossi, M., Azzari, C., Blumberg, B. S., and Vierucci, A. Pathogenesis of post-transfusion viral hepatitis in children with β-thalassemia. Hepatology, 19: 558-568, 1994.
55. Uchida, T., Shimojima, M., Gotoh, K., Shikata, T., Tanaka, E., and Kiyosawa, K. "Silent" hepatitis B virus mutants are responsible for non-A, non-B, non-C, non-D, non-E hepatitis. Microbiol. Immunol., 38: 281-285, 1994.
56. Takada, S., Tsuchida, N., Kobayashi, M., and Koike, K. Disruption of the function of tumor-suppressor gene p53 by the hepatitis B virus X protein and hepatocarcinogenesis. J. Cancer Res. Clin. Oncol., 121: 593-601, 1995.
57. Wang, W., London, W. T., and Feitelson, M. A. Hepatitis B x antigen in hepatitis B virus carrier patients with liver cancer. Cancer Res., 51: 4971-4977, 1991.
58. Diamantis, I. D., McGandy, C. E., Chen, T. J., Liaw, Y. F., Gudat, F., and Bianchi, L. Hepatitis B x-gene expression in hepatocellular carcinoma. J. Hepatol., 15: 400-403, 1992.
59. Paterlini, P., Poussin, K., Kew, M., Franco, D., and Brechet, C. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology, 21: 313-321, 1995.
60. Nishada, N., Fakuda, Y., Kokuryu, H., Toguchida, J., Yandell, D. W., Ikenega, M., Imura, H., and Ishizaki, K. Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma. Cancer Res., 53: 368-372, 1993.
61. Buetow, K. H., Sheffield, V. C., Zhu, M., Zhou, T., Shen, F. M., Hino, O., Smith, M., McMahon, B. J., Lanier, A. P., London, W. T., Redeker, A. G., and Govindarajan, S. Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. Proc. Natl. Acad. Sci. USA, 89: 9622-9626, 1992.
62. Hosono, S., Chou, M. J., Lee, C. S., and Shin, C. Infrequent mutation of p53 gene in hepatitis B virus positive primary hepatocellular carcinomas. Oncogene, 8: 491-496, 1993.
63. Challen, C., Lunec, J., Warren, W., Collier, J., and Bassendine, M. F. Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain. Hepatology, 16: 1362-1366, 1992.
64. Chen, Y., Tang, Z. Y., and Li, J. Expression of mutant p53 in chronic HBV infection and hepatocellular carcinoma. Chinese J. Oncol., 16: 184-187, 1994.
65. Henkler, F., Waseem, N., Golding, M. H. C., Allison, M. R., and Koshy, R. Mutant p53 but not hepatitis B virus X protein is present in hepatitis B virus-related human hepatocellular carcinoma. Cancer Res., 55: 6084-6091, 1995.
66. Popper, H., Roth, L., Purcell, R. H., Tennant, B. C., and Gerin, J. L. Hepatocarcinogenicity of the woodchuck hepatitis virus. Proc. Natl. Acad. Sci. USA, 84: 866-870, 1987.